Latest Financials News

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Sky Metals has launched a major drilling campaign at its Tallebung Tin Project, aiming to expand high-grade resources and update its Mineral Resource Estimate. Meanwhile, a metallurgical breakthrough at Doradilla confirms its potential as a second key tin asset.

Ballard Mining has raised $61 million through a well-supported placement to fund an aggressive drilling program and early development works at its Mt Ida Gold Project, positioning the company for a Final Investment Decision.

Strickland Metals has announced a maiden inferred resource of 1.2 million ounces of gold at its Gradina Deposit, lifting the total Rogozna Project resources by 16% to 8.6 million ounces gold equivalent. The company plans an ambitious 60,000-metre drilling campaign in 2026 to further expand and define its Serbian gold-base metals assets.

Guzman y Gomez has secured a multi-year exclusive delivery partnership with Uber Eats in Australia, aiming to accelerate growth and enhance customer convenience. Delivery now accounts for over a quarter of GYG’s Australian sales, underscoring its strategic importance.

Delta Lithium Limited reports strong drilling results at its Mt Ida and Yinnetharra projects, alongside successful production of battery-grade lithium carbonate and a robust financial position.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Bounty Oil & Gas has announced a significant board renewal, including the appointment of Kane Marshall as Chairman and the retirement of long-serving CEO Philip Kelso. These leadership changes mark a new chapter as the company pursues growth in its Australian oil and gas assets.

Korvest has reported a solid first half for FY26 with revenue up 17.9% and EBIT rising 36.3%, underpinned by major project wins and operational upgrades. The Kilburn redevelopment is progressing on schedule, setting the stage for further growth.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.